Michael S. Hofman

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis et al. · The Lancet · 2020 · 2K citations

Medicine, Nuclear Medicine, Oncology +17

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

Michael S. Hofman, John Violet, Rodney J. Hicks et al. · The Lancet Oncology · 2018 · 1.1K citations

Medicine, Nuclear Medicine, Oncology +14

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet · 2021 · 1.1K citations

Medicine, Oncology, Pharmacology +12

Somatostatin Receptor Imaging with⁶⁸Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation

Michael S. Hofman, Eddie Lau, Rodney J. Hicks · Radiographics · 2015 · 556 citations

Medicine, Nuclear Medicine, Radiology +17

Dosimetry of ¹⁷⁷Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes

John Violet, Price Jackson, Justin Ferdinandus et al. · Journal of Nuclear Medicine · 2018 · 486 citations · Full text

Medicine, Nuclear Medicine, Oncology +17